111 related articles for article (PubMed ID: 27239089)
1. TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data.
Chen Z; Guo J; Zhang K; Guo Y
Dis Markers; 2016; 2016():4639575. PubMed ID: 27239089
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway.
Saba KH; Difilippo V; Kovac M; Cornmark L; Magnusson L; Nilsson J; van den Bos H; Spierings DC; Bidgoli M; Jonson T; Sumathi VP; Brosjö O; Staaf J; Foijer F; Styring E; Nathrath M; Baumhoer D; Nord KH
J Pathol; 2024 Feb; 262(2):147-160. PubMed ID: 38010733
[TBL] [Abstract][Full Text] [Related]
3. Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma.
Das S; Idate R; Regan DP; Fowles JS; Lana SE; Thamm DH; Gustafson DL; Duval DL
Commun Biol; 2021 Oct; 4(1):1178. PubMed ID: 34635775
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma.
Lietz CE; Garbutt C; Barry WT; Deshpande V; Chen YL; Lozano-Calderon SA; Wang Y; Lawney B; Ebb D; Cote GM; Duan Z; Hornicek FJ; Choy E; Petur Nielsen G; Haibe-Kains B; Quackenbush J; Spentzos D
Sci Rep; 2020 Mar; 10(1):4409. PubMed ID: 32157112
[TBL] [Abstract][Full Text] [Related]
5. Patterns of structural variants within TP53 introns and relocation of the TP53 promoter: a commentary
Beird HC; Lin D; Lazar AJ; Futreal PA
J Pathol; 2024 Jun; 263(2):131-134. PubMed ID: 38482738
[TBL] [Abstract][Full Text] [Related]
6. Investigation of cellular communication and signaling pathways in tumor microenvironment for high TP53-expressing osteosarcoma cells through single-cell RNA sequencing.
Xiong K; Fang Y; Qiu B; Chen C; Huang N; Liang F; Huang C; Lu T; Zheng L; Zhao J; Zhu B
Med Oncol; 2024 Mar; 41(5):93. PubMed ID: 38526643
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of NT5DC family-based prognostic model in osteosarcoma.
Chang X; Jiang Y; Wang Z; Lou Z
Asian J Surg; 2024 Jan; 47(1):531-532. PubMed ID: 37777411
[No Abstract] [Full Text] [Related]
8. TP53 in Biology and Treatment of Osteosarcoma.
Synoradzki KJ; Bartnik E; Czarnecka AM; Fiedorowicz M; Firlej W; Brodziak A; Stasinska A; Rutkowski P; Grieb P
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503094
[TBL] [Abstract][Full Text] [Related]
9. Exploring the future of research in the Tp53 field.
Levine AJ
Cell Death Differ; 2022 May; 29(5):893-894. PubMed ID: 35383291
[No Abstract] [Full Text] [Related]
10. The pharmacogenomics of osteosarcoma.
Serra M; Hattinger CM
Pharmacogenomics J; 2017 Jan; 17(1):11-20. PubMed ID: 27241064
[TBL] [Abstract][Full Text] [Related]
11. HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies.
Zhang Q; Liu F; Wang B; Li Z; Zhou D; Yang Q; Dong J; Li J
Medicine (Baltimore); 2016 Jun; 95(23):e3661. PubMed ID: 27281068
[TBL] [Abstract][Full Text] [Related]
12. Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches.
Singh R; Lehrer EJ; Ko S; Peterson J; Lou Y; Porter AB; Kotecha R; Brown PD; Zaorsky NG; Trifiletti DM
Radiother Oncol; 2020 Mar; 144():165-179. PubMed ID: 31812932
[TBL] [Abstract][Full Text] [Related]
13. TCGA molecular groups of endometrial cancer: Pooled data about prognosis.
Raffone A; Travaglino A; Mascolo M; Carbone L; Guida M; Insabato L; Zullo F
Gynecol Oncol; 2019 Nov; 155(2):374-383. PubMed ID: 31472940
[TBL] [Abstract][Full Text] [Related]
14. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: A meta-analysis.
Lee JH; Jeong H; Choi JW; Oh HE; Kim YS
Medicine (Baltimore); 2018 Oct; 97(42):e12862. PubMed ID: 30334995
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.
Zhuang R; Li S; Li Q; Guo X; Shen F; Sun H; Liu T
PLoS One; 2017; 12(8):e0182562. PubMed ID: 28796802
[TBL] [Abstract][Full Text] [Related]
17. Somatic TP53 Mutations in the Era of Genome Sequencing.
Hainaut P; Pfeifer GP
Cold Spring Harb Perspect Med; 2016 Nov; 6(11):. PubMed ID: 27503997
[TBL] [Abstract][Full Text] [Related]
18. K-nearest-neighbor algorithm to predict the survival time and classification of various stages of oral cancer: a machine learning approach.
Siddalingappa R; Kanagaraj S
F1000Res; 2022; 11():70. PubMed ID: 38046542
[No Abstract] [Full Text] [Related]
19. Blockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma.
Nastasi N; Pasha A; Bruno G; Subbiani A; Pietrovito L; Leo A; Scala L; de Simone L; Casazza G; Lunardi F; Taddei ML; Tamburini A; Tondo A; Favre C; Calvani M
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835437
[TBL] [Abstract][Full Text] [Related]
20. Establishment and Characterization of Multi-Drug Resistant p53-Negative Osteosarcoma SaOS-2 Subline.
Boichuk S; Bikinieva F; Valeeva E; Dunaev P; Vasileva M; Kopnin P; Mikheeva E; Ivoilova T; Mustafin I; Galembikova A
Diagnostics (Basel); 2023 Aug; 13(16):. PubMed ID: 37627905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
